A simplified pre-bronchoscopy risk stratification model for patients with suspected lung cancer based on age, smoking status, and serum CEA

Background Bronchoscopy is commonly used in the diagnostic work-up of patients with suspected lung cancer, yet clinicians often lack a simple tool to estimate malignancy risk before the procedure in patients already being considered for bronchoscopic evaluation. Most existing prediction models focus on the malignant potential of pulmonary nodules and rely heavily on imaging features, limiting their applicability to the pre-bronchoscopy setting. This study aimed to develop and internally validate a simplified pre-bronchoscopy risk stratification model using routinely available clinical variables. Methods This single-center retrospective cohort study included 336 patients undergoing evaluation for suspected lung cancer. Candidate predictors were restricted to variables available before bronchoscopy and selected based on clinical relevance, routine availability, and data completeness. From 32 candidate predictors, LASSO regression retained 18 variables, which were entered into a multivariable logistic regression model followed by elimination based on statistical and clinical criteria. A simplified model was then constructed and presented as a nomogram. Model performance was assessed in the full cohort, with bootstrap internal validation using 1,000 resamples; the post-LASSO elimination steps were not repeated within bootstrap samples. Results Three independent predictors were identified: age (odds ratio [OR] = 1.045, 95% confidence interval [CI]: 1.017–1.073, P < 0.001), smoking status (OR = 3.216, 95% CI: 1.847–5.598, P < 0.001), and serum carcinoembryonic antigen (CEA) [ln(CEA + 1), per unit increase] (OR = 4.989, 95% CI: 3.095–8.043, P < 0.001). After bootstrap optimism correction, the model demonstrated a corrected C-statistic of 0.837 and a calibration slope of 0.972, with acceptable discrimination and calibration. In biomarker analysis, serum CEA at a cut-off value of 4.57 ng/mL showed high specificity (94%) but moderate sensitivity (52%), whereas bronchoalveolar lavage fluid (BALF) CEA at 22.6 ng/mL showed higher sensitivity (71%) but lower specificity (57%). Mediation analysis indicated that serum CEA partially mediates the association between smoking and lung cancer (indirect effect: 0.09, 95% CI: 0.02–0.15, P = 0.004). Restricted cubic spline analysis showed a linear association between serum CEA and lung cancer risk, with no nonlinearity ( P = 0.514). Conclusions We developed a simplified clinically oriented pre-bronchoscopy risk stratification model based on age, smoking status, and serum CEA levels. The model estimates malignancy probability within a selected bronchoscopy population and does not determine procedural appropriateness or the optimal diagnostic pathway. For patients already being considered for bronchoscopic evaluation because of suspected lung cancer, this model may serve as an adjunctive tool for estimating malignancy risk and informing clinical prioritization. Given the sample size relative to the number of candidate predictors, the model should be regarded as exploratory and supportive rather than determinative. External validation in broader and more diverse populations is required before clinical implementation.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-18
DOI
https://doi.org/10.3389/fonc.2026.1919825
Primary Topic
Lung Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A simplified pre-bronchoscopy risk stratification model for patients with suspected lung cancer based on age, smoking status, and serum CEA

Guofu Lin, Shuling Wang, Biying Wang, Yuehua Chen et al.
3 links
Frontiers in Oncology
Lung Cancer Diagnosis and Treatment
article

A simplified pre-bronchoscopy risk stratification model for patients with suspected lung cancer based on age, smoking status, and serum CEA

Guofu Lin, Shuling Wang, Biying Wang, Yuehua Chen, Aiming Zeng, Jiefeng Huang, Lifang Fu
article en

Abstract

Background Bronchoscopy is commonly used in the diagnostic work-up of patients with suspected lung cancer, yet clinicians often lack a simple tool to estimate malignancy risk before the procedure in patients already being considered for bronchoscopic evaluation. Most existing prediction models focus on the malignant potential of pulmonary nodules and rely heavily on imaging features, limiting their applicability to the pre-bronchoscopy setting. This study aimed to develop and internally validate a simplified pre-bronchoscopy risk stratification model using routinely available clinical variables. Methods This single-center retrospective cohort study included 336 patients undergoing evaluation for suspected lung cancer. Candidate predictors were restricted to variables available before bronchoscopy and selected based on clinical relevance, routine availability, and data completeness. From 32 candidate predictors, LASSO regression retained 18 variables, which were entered into a multivariable logistic regression model followed by elimination based on statistical and clinical criteria. A simplified model was then constructed and presented as a nomogram. Model performance was assessed in the full cohort, with bootstrap internal validation using 1,000 resamples; the post-LASSO elimination steps were not repeated within bootstrap samples. Results Three independent predictors were identified: age (odds ratio [OR] = 1.045, 95% confidence interval [CI]: 1.017–1.073, P < 0.001), smoking status (OR = 3.216, 95% CI: 1.847–5.598, P < 0.001), and serum carcinoembryonic antigen (CEA) [ln(CEA + 1), per unit increase] (OR = 4.989, 95% CI: 3.095–8.043, P < 0.001). After bootstrap optimism correction, the model demonstrated a corrected C-statistic of 0.837 and a calibration slope of 0.972, with acceptable discrimination and calibration. In biomarker analysis, serum CEA at a cut-off value of 4.57 ng/mL showed high specificity (94%) but moderate sensitivity (52%), whereas bronchoalveolar lavage fluid (BALF) CEA at 22.6 ng/mL showed higher sensitivity (71%) but lower specificity (57%). Mediation analysis indicated that serum CEA partially mediates the association between smoking and lung cancer (indirect effect: 0.09, 95% CI: 0.02–0.15, P = 0.004). Restricted cubic spline analysis showed a linear association between serum CEA and lung cancer risk, with no nonlinearity ( P = 0.514). Conclusions We developed a simplified clinically oriented pre-bronchoscopy risk stratification model based on age, smoking status, and serum CEA levels. The model estimates malignancy probability within a selected bronchoscopy population and does not determine procedural appropriateness or the optimal diagnostic pathway. For patients already being considered for bronchoscopic evaluation because of suspected lung cancer, this model may serve as an adjunctive tool for estimating malignancy risk and informing clinical prioritization. Given the sample size relative to the number of candidate predictors, the model should be regarded as exploratory and supportive rather than determinative. External validation in broader and more diverse populations is required before clinical implementation.

Frontiers in OncologyVol. 16
Fujian Medical University (CN), First Affiliated Hospital of Fujian Medical University (CN)
Fujian Medical University
Good health and well-being
Lung Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon